Literature DB >> 22727042

Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

F Galban-Horcajo1, A M Fitzpatrick, A J Hutton, S M Dunn, G Kalna, K M Brennan, S Rinaldi, R K Yu, C S Goodyear, H J Willison.   

Abstract

BACKGROUND: Measurement of anti-GM1 IgM antibodies in multifocal motor neuropathy (MMN) sera is confounded by relatively low sensitivity that limits clinical usefulness. Combinatorial assay methods, in which antibodies react to heteromeric complexes of two or more glycolipids, are being increasingly applied to this area of diagnostic testing.
METHODS: A newly developed combinatorial glycoarray able to identify antibodies to 45 different heteromeric glycolipid complexes and their 10 individual glycolipid components was applied to a randomly selected population of 33 MMN cases and 57 normal or disease controls. Comparison with an enzyme-linked immunosorbent assay (ELISA) was conducted for selected single glycolipids and their complexes.
RESULTS: By ELISA, 22/33 MMN cases had detectable anti-GM1 IgM antibodies, whereas 19/33 MMN samples were positive for anti-GM1 antibodies by glycoarray. Analysis of variance (anova) revealed that of the 55 possible single glycolipids and their 1:1 complexes, antibodies to the GM1:galactocerebroside (GM1:GalC) complex were most significantly associated with MMN, returning 33/33 MMN samples as positive by glycoarray and 29/33 positive by ELISA. Regression analysis revealed a high correlation in absolute values between ELISA and glycoarray. Receiver operator characteristic analysis revealed insignificantly different diagnostic performance between the two methods. However, the glycoarray appeared to offer slightly improved sensitivity by identifying antibodies in four ELISA-negative samples.
CONCLUSIONS: The use of combinatorial glycoarray or ELISA increased the diagnostic sensitivity of anti-glycolipid antibody testing in this cohort of MMN cases, without significantly affecting specificity, and may be a useful assay modification for routine clinical screening.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727042      PMCID: PMC3896049          DOI: 10.1111/j.1468-1331.2012.03767.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  29 in total

1.  Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone.

Authors:  A Pestronk; R Choksi; G Blume; G Lopate
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

Review 2.  Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding.

Authors:  S Rinaldi; K M Brennan; H J Willison
Journal:  Prog Lipid Res       Date:  2009-09-06       Impact factor: 16.195

3.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

4.  Detection of anti-GM1 ganglioside antibodies in patients with neuropathy by a novel latex agglutination assay.

Authors:  A Alaedini; N Latov
Journal:  J Immunoassay       Date:  2000-11

5.  Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies.

Authors:  Eduardo Nobile-Orazio; Claudia Giannotta; Chiara Briani
Journal:  J Neuroimmunol       Date:  2009-12-16       Impact factor: 3.478

6.  Ganglioside complexes as new target antigens in Guillain-Barré syndrome.

Authors:  Ken-ichi Kaida; Daiji Morita; Mami Kanzaki; Keiko Kamakura; Kazuo Motoyoshi; Minako Hirakawa; Susumu Kusunoki
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

7.  Cloning of human anti-GM1 antibodies from motor neuropathy patients.

Authors:  H J Willison; G Paterson; P G Kennedy; J Veitch
Journal:  Ann Neurol       Date:  1994-04       Impact factor: 10.422

8.  ELISA-type titertray assay of IgM anti-GM1 autoantibodies.

Authors:  E Bech; J Jakobsen; T F Orntoft
Journal:  Clin Chem       Date:  1994-07       Impact factor: 8.327

9.  Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation.

Authors:  G Paterson; G Wilson; P G Kennedy; H J Willison
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

Review 10.  Antiglycolipid antibodies in motor neuropathies.

Authors:  N Baumann; M L Harpin; Y Marie; K Lemerle; B Chassande; P Bouche; V Meininger; R K Yu; J M Léger
Journal:  Ann N Y Acad Sci       Date:  1998-06-19       Impact factor: 5.691

View more
  15 in total

Review 1.  The pathogenesis of multifocal motor neuropathy and an update on current management options.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Ruxandra Iancu Ferfoglia
Journal:  Ther Adv Neurol Disord       Date:  2015-05       Impact factor: 6.570

Review 2.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

Review 3.  Diagnostics of dysimmune peripheral neuropathies.

Authors:  Diego Franciotta; Matteo Gastaldi; Luana Benedetti; Giampaola Pesce; Tiziana Biagioli; Francesco Lolli; Gianna Costa; Cristina Melis; Francesca Andreetta; Ornella Simoncini; Claudia Giannotta; Elena Bazzigaluppi; Raffaella Fazio; Roberta Bedin; Diana Ferraro; Sara Mariotto; Sergio Ferrari; Elisabetta Galloni; Valentina De Riva; Elisabetta Zardini; Andrea Cortese; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

4.  Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study.

Authors:  Lotte Vlam; Sanne Piepers; Nadia A Sutedja; Bart C Jacobs; Anne P Tio-Gillen; Marloes Stam; Hessel Franssen; Jan H Veldink; Elisabeth A Cats; Nicolette C Notermans; Andries C Bloem; Renske I Wadman; W-Ludo van der Pol; Leonard H van den Berg
Journal:  J Neurol       Date:  2015-01-01       Impact factor: 4.849

5.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

Review 6.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

7.  Subtype-specific therapy for autoimmune neuropathies?

Authors:  Eric Lancaster; Steven S Scherer
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-09-24

Review 8.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

9.  Complement activity is associated with disease severity in multifocal motor neuropathy.

Authors:  Lotte Vlam; Elisabeth A Cats; Oliver Harschnitz; Marc D Jansen; Sanne Piepers; Jan Herman Veldink; Hessel Franssen; Abraham C J Stork; Erik Heezius; Suzan H M Rooijakkers; Bjorn L Herpers; Jos A van Strijp; Leonard H van den Berg; W Ludo van der Pol
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-06-25

Review 10.  Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.

Authors:  Victoria H Lawson; W David Arnold
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-05       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.